Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) insider Dana Pizzuti sold 9,583 shares of Crinetics Pharmaceuticals stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $34.57, for a total transaction of $331,284.31. Following the completion of the transaction, the insider now directly owns 5,911 shares of […]
Sanders Morris Harris LLC acquired a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 18,600 shares of the company’s stock, valued at approximately $336,000. A number of other institutional investors and […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price objective boosted by Evercore ISI from $41.00 to $48.00 in a research note published on Monday morning, MarketBeat Ratings reports. They currently have an outperform rating on the stock. CRNX has been the topic of a number of other research reports. Cantor Fitzgerald reaffirmed an overweight […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target upped by Oppenheimer from $40.00 to $46.00 in a report released on Monday morning, Marketbeat reports. The firm currently has an outperform rating on the stock. Other research analysts also recently issued reports about the company. HC Wainwright reissued a buy rating and issued a […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report)’s share price gapped up before the market opened on Tuesday after Evercore ISI raised their price target on the stock from $41.00 to $48.00. The stock had previously closed at $26.08, but opened at $27.00. Evercore ISI currently has an outperform rating on the stock. Crinetics Pharmaceuticals […]